Richard Weiten
5PUBLICATIONS
3CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Oct 07, 2025
Expression and therapeutic potential of TROP2 in cisplatin-resistant germ cell tumors.Laurenz Sperber, Melanie von Brandenstein, Carolina Kessler
|Sep 01, 2025
TROP-2 overexpression in papillary renal cell carcinoma supports its potential as a therapeutic target for antibody-drug-conjugate therapy.Carolina Kessler, Melanie von Brandenstein, Niklas Klümper
|Dec 20, 2024
The New Tumour Biomarker miRNA-371-3p Influences Cisplatin Sensitivity of Testicular Germ Cell Tumour Cell Lines.Richard Weiten, Theadora Engler, Hubert Schorle
|Jul 29, 2024
Exploring membranous NECTIN-4 expression patterns and enfortumab vedotin response in prostate cancer.Richard Weiten, Marit Bernhardt, Max Niemann
|Jun 19, 2024
Preclinical evidence for the use of anti-Trop-2 antibody-drug conjugate Sacituzumab govitecan in cerebral metastasized castration-resistant prostate cancer.Richard Weiten, Max Niemann, Eduard Below
Pageof 1
